amifostine anhydrous has been researched along with busulfan in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bensinger, WI; Chauncey, TR; Gooley, TA; Holmberg, L; Lilleby, K; Lloid, ME; Schubert, MM | 1 |
| Appelbaum, FR; Benesch, M; Deeg, HJ; McDonald, GB; Schubert, M | 1 |
| Etebari, M; Ghassemi-Barghi, N; Jafarian-Dehkordi, A | 1 |
1 review(s) available for amifostine anhydrous and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for amifostine anhydrous and busulfan
| Article | Year |
|---|---|
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study.
Topics: Adult; Amifostine; Busulfan; Cause of Death; Cytoprotection; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Pilot Projects; Siblings; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2003 |
4 other study(ies) available for amifostine anhydrous and busulfan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Busulfan; Feasibility Studies; Female; Flushing; Hematopoietic Stem Cell Transplantation; Humans; Hypotension; Male; Melphalan; Middle Aged; Mucous Membrane; Neoplasms; Pilot Projects; Protective Agents; Sneezing; Thiotepa; Transplantation, Autologous; Vomiting | 2000 |
Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells.
Topics: Amifostine; Antimutagenic Agents; Antineoplastic Agents, Alkylating; Busulfan; Cell Culture Techniques; Comet Assay; Cytoprotection; DNA Damage; Dose-Response Relationship, Drug; Glutathione; Hep G2 Cells; Humans; Oxidative Stress; Reactive Oxygen Species | 2017 |